This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/mesh/concept/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/bindingdb/
n5http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/pubchem-compound/
n13http://bio2rdf.org/drugbank:
n4http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06594/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06594
rdf:type
n6:Drug
n6:description
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
n6:generalReferences
# Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15289999 # Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18368944 # Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17917564
n6:group
approved investigational
n6:halfLife
<2 hours
n6:indication
Agomelatine is indicated for the treatment of major depressive episodes in adults.
owl:sameAs
n11:DB06594 n13:DB06594
dcterms:title
Agomelatine
adms:identifier
n4:D02578 n5:82148 n8:74141 n9:DB06594 n12:50035179 n18:Agomelatine n19:PA165958363
n6:mechanismOfAction
The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
n6:synonym
Valdoxan
n6:proteinBinding
> 95%
n6:synthesisReference
Jean-Claude Souvie, Isaac Gonzalez Blanco, Gilles Thominot, Genevieve Chapuis, Stephane Horvath, Gerard Damien, "Process for the synthesis and crystalline form of agomelatine." U.S. Patent US20050182276, issued August 18, 2005.
n14:hasConcept
n15:M0390447
n6:IUPAC-Name
n7:271B4D12-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B4D18-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B4D17-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B4D14-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B4D15-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B4D16-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B4D10-363D-11E5-9242-09173F13E4C5 n7:271B4D28-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B4D11-363D-11E5-9242-09173F13E4C5 n7:271B4D0E-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B4D0F-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:N06AX22
n6:H-Bond-Acceptor-Count
n7:271B4D1E-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B4D1F-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B4D19-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B4D1A-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B4D1C-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B4D1B-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B4D1D-363D-11E5-9242-09173F13E4C5
n6:absorption
Bioavailability is less than 5%.
n6:casRegistryNumber
138112-76-2
n6:category
n6:Bioavailability
n7:271B4D24-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B4D26-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B4D27-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B4D23-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B4D22-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B4D25-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B4D13-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B4D20-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B4D21-363D-11E5-9242-09173F13E4C5